These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 35793398)

  • 1. Pharmacotherapy for Alzheimer's disease: what's new on the horizon?
    Khoury R; Gallop A; Roberts K; Grysman N; Lu J; Grossberg GT
    Expert Opin Pharmacother; 2022 Aug; 23(11):1305-1323. PubMed ID: 35793398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials.
    Bullain S; Doody R
    J Neurochem; 2020 Sep; 155(2):120-136. PubMed ID: 32277473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs.
    Lozupone M; Solfrizzi V; D'Urso F; Di Gioia I; Sardone R; Dibello V; Stallone R; Liguori A; Ciritella C; Daniele A; Bellomo A; Seripa D; Panza F
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):319-335. PubMed ID: 32772738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease drug development pipeline: 2017.
    Cummings J; Lee G; Mortsdorf T; Ritter A; Zhong K
    Alzheimers Dement (N Y); 2017 Sep; 3(3):367-384. PubMed ID: 29067343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solanezumab for Alzheimer's disease.
    Samadi H; Sultzer D
    Expert Opin Biol Ther; 2011 Jun; 11(6):787-98. PubMed ID: 21504387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
    Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
    Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapeutic combinations for the treatment of Alzheimer's disease.
    Nagata T; Shinagawa S; Nakajima S; Noda Y; Mimura M
    Expert Opin Pharmacother; 2022 Apr; 23(6):727-737. PubMed ID: 35230200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease drug development pipeline: 2022.
    Cummings J; Lee G; Nahed P; Kambar MEZN; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2022; 8(1):e12295. PubMed ID: 35516416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
    Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
    Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's drug-development pipeline: 2016.
    Cummings J; Morstorf T; Lee G
    Alzheimers Dement (N Y); 2016 Nov; 2(4):222-232. PubMed ID: 29067309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease drug development pipeline: 2018.
    Cummings J; Lee G; Ritter A; Zhong K
    Alzheimers Dement (N Y); 2018; 4():195-214. PubMed ID: 29955663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
    Cummings J; Ritter A; Zhong K
    J Alzheimers Dis; 2018; 64(s1):S3-S22. PubMed ID: 29562511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
    Rygiel K
    Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.
    Panza F; Seripa D; Solfrizzi V; Imbimbo BP; Lozupone M; Leo A; Sardone R; Gagliardi G; Lofano L; Creanza BC; Bisceglia P; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Emerg Drugs; 2016 Dec; 21(4):377-391. PubMed ID: 27678025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
    Avgerinos KI; Ferrucci L; Kapogiannis D
    Ageing Res Rev; 2021 Jul; 68():101339. PubMed ID: 33831607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current Clinical Trials in the Treatment of Alzheimer's Disease].
    Tamaoka A
    Brain Nerve; 2020 Jan; 72(1):23-34. PubMed ID: 31907330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug development in Alzheimer's disease: the path to 2025.
    Cummings J; Aisen PS; DuBois B; Frölich L; Jack CR; Jones RW; Morris JC; Raskin J; Dowsett SA; Scheltens P
    Alzheimers Res Ther; 2016 Sep; 8():39. PubMed ID: 27646601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease.
    Budd Haeberlein S; O'Gorman J; Chiao P; Bussière T; von Rosenstiel P; Tian Y; Zhu Y; von Hehn C; Gheuens S; Skordos L; Chen T; Sandrock A
    J Prev Alzheimers Dis; 2017; 4(4):255-263. PubMed ID: 29181491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
    Piazza F; Winblad B
    J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy Developments in Alzheimer's Disease].
    Grimmer T
    Fortschr Neurol Psychiatr; 2022 Jul; 90(7-08):352-360. PubMed ID: 35588740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.